Psoriasis Clinical Trials in Manchester
View 34 new treatments for Psoriasis in Manchester, NH. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Portsmouth + 1 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
UCB Cares
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Portsmouth + 1 more
This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Ixekizumab + Tirzepatide for Psoriasis
Eli Lilly Clinic, Portsmouth + 1 more
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Tildrakizumab for Nail Psoriasis
Sun Clinic, Portsmouth + 1 more
This trial is testing Tildrakizumab, a medication that helps reduce inflammation, in patients with moderate to severe nail psoriasis. These patients often do not respond well to standard treatments. Tildrakizumab works by blocking a protein that causes inflammation, helping to calm the immune system and reduce symptoms. Tildrakizumab has been shown to be effective in improving skin manifestations as well as enhancing quality of life outcomes in patients with psoriasis.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
TAK-279 for Psoriasis
Takeda Clinic, Portsmouth + 1 more
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Study Director
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Portsmouth + 1 more
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
ESK-001 for Plaque Psoriasis
Alumis Clinic, Portsmouth + 1 more
This trial involves patients with plaque psoriasis who have already participated in a previous study of ESK-001. They will continue to receive ESK-001 to see if it helps reduce their symptoms. The study will last for an extended period.Show More
Waitlist
No Placebo Trial
Phase 2
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Page 1 of 1
Frequently Asked Questions
Explore related conditions